The best hybrid, 1173, is a full VDR agonist, as assessed by several criteria, and an efficacious antiproliferative agent against both 1,25D-sensitive (SCC25, AT84) and 1α,25(OH)2D3-resistant (SCC4) squamous carcinoma cell lines. Here, VDR is linked to squamous cell carcinoma.